Clinical Trials of Limbal Stem Cell Deficiency Treated with Oral Mucosal Epithelial Cells

Int J Mol Sci. 2020 Jan 9;21(2):411. doi: 10.3390/ijms21020411.

Abstract

The corneal surface is an essential organ necessary for vision, and its clarity must be maintained. The corneal epithelium is renewed by limbal stem cells, located in the limbus and in palisades of Vogt. Palisades of Vogt maintain the clearness of the corneal epithelium by blocking the growth of conjunctival epithelium and the invasion of blood vessels over the cornea. The limbal region can be damaged by chemical burns, physical damage (e.g., by contact lenses), congenital disease, chronic inflammation, or limbal surgeries. The degree of limbus damage is associated with the degree of limbal stem cells deficiency (partial or total). For a long time, the only treatment to restore vision was grafting part of the healthy cornea from the other eye of the patient or by transplanting a cornea from cadavers. The regenerative medicine and stem cell therapies have been applied to restore normal vision using different methodologies. The source of stem cells varies from embryonic stem cells, mesenchymal stem cells, to induced pluripotent stem cells. This review focuses on the use of oral mucosa epithelial stem cells and their use in engineering cell sheets to treat limbal stem cell deficient patients.

Keywords: cell sheet; clinical trial; limbal stem cell deficiency; tissue engineering.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic*
  • Epithelial Cells / transplantation*
  • Humans
  • Limbus Corneae / pathology*
  • Mouth Mucosa / cytology*
  • Stem Cells / pathology*
  • Tissue Engineering